Results 11 to 20 of about 258,912 (200)
Anticholinergic syndrome in a patient with schizophrenia
European Psychiatry, 2022 Introduction Anticholinergic syndrome (AS) is a complication that can appear due to different drugs with antimuscarinic effects, such as antihistamines, alkaloids, antipsychotics, tricyclic antidepressives or anesthetics, and it is characterized by ...
O. Marco Estrada +5 more
doaj +1 more source
Clozapine induced oesophagitis: A case report
European Psychiatry, 2022 Introduction There are several case reports describing clozapine side effects such as agranulocytosis, constipation,tachycardia but rarely cases describing oesophagitis caused by clozapine were reported.
N. Herch +4 more
doaj +1 more source
Schizophrenia And Polycystic Ovary Syndrome: A Case Report
European Psychiatry, 2022 Introduction Patients with Polycystic ovary syndrome (PCOS) have increased vulnerability to psychiatric disorders, particularly a tendency to depression and anxiety, as well as schizophrenia.
M. Turki +6 more
doaj +1 more source
Imunne system and schyzophrenia
European Psychiatry, 2022 Introduction Schizophrenia affects approximately 1% of the world population, having a devastating impact not only in patients but in all society.
A. Almeida, T. Teixeira, J. Quarenta
doaj +1 more source
European Psychiatry, 2022 Introduction Suppressor of cytokine signaling (SOCS) proteins are the critical negative regulators of immune responses that exert their effects by inhibiting the Jak/Stat signaling pathway. Objectives To investigate quantitative detection of methylated
H.M. Aytac +3 more
doaj +1 more source
European Psychiatry, 2022 Introduction According to current knowledge inflammation seems to be strongly associated with pathogenesis of schizophrenia. Multiple studies and meta-analyses showed increased levels of inflammatory markers in plasma of schizophrenia patients ...
A. Michalczyk +5 more
doaj +1 more source
European Psychiatry, 2022 Introduction Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission.
I. Winter +3 more
doaj +1 more source
First-rank symptoms: Past, present and future
European Psychiatry, 2021 Introduction Conceptualising Schneider’s first-rank symptoms (FRS) as a diagnostic test whose performance can be measured in terms of sensitivity and specificity involves some issues that require reflection. The first formal proposal was contained in a
B. Jorge +3 more
doaj +1 more source
Cognitive impairment in treatment-refractory schizophrenia and type i diabetes. A case
European Psychiatry, 2021 Introduction Even when sharing etiologic factors, the incidence of DM-1 is low in patients with schizophrenia. Both diseases can lead to cognitive impairment, but its difficult to define its origin.
L. Soldado Rodriguez +3 more
doaj +1 more source
Alternative initiation regimen of paliperidone palmitate long-acting injectable
European Psychiatry, 2022 Introduction Long-acting injectable antipsychotics (LAIs) hold an important place in the treatment of psychosis. Knowledge of the best way to administer LAIs is important to maximize the efficacy and minimize the side-effects Objectives To assess the ...
I.E. Menendez Gil +2 more
doaj +1 more source